Bicara Net Debt from 2010 to 2026
| BCAX Stock | 14.97 0.02 0.13% |
Net Debt | First Reported 2010-12-31 | Previous Quarter -440.1 M | Current Value -418.1 M | Quarterly Volatility 177.5 M |
Check Bicara Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bicara Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 225.8 K, Net Interest Income of 17.6 M or Interest Income of 17.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.82. Bicara financial statements analysis is a perfect complement when working with Bicara Therapeutics Valuation or Volatility modules.
Bicara | Net Debt | Build AI portfolio with Bicara Stock |
The evolution of Net Debt for Bicara Therapeutics Common provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Bicara Therapeutics compares to historical norms and industry peers.
Latest Bicara Therapeutics' Net Debt Growth Pattern
Below is the plot of the Net Debt of Bicara Therapeutics Common over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Bicara Therapeutics' Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bicara Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Debt | 10 Years Trend |
|
Net Debt |
| Timeline |
Bicara Net Debt Regression Statistics
| Arithmetic Mean | (95,938,683) | |
| Coefficient Of Variation | (185.01) | |
| Mean Deviation | 140,370,457 | |
| Median | (4,158,000) | |
| Standard Deviation | 177,499,718 | |
| Sample Variance | 31506.2T | |
| Range | 484.8M | |
| R-Value | (0.73) | |
| Mean Square Error | 15934.2T | |
| R-Squared | 0.53 | |
| Significance | 0.001 | |
| Slope | (25,489,584) | |
| Total Sum of Squares | 504098.4T |
Bicara Net Debt History
Other Fundumenentals of Bicara Therapeutics
Bicara Therapeutics Net Debt component correlations
Click cells to compare fundamentals
About Bicara Therapeutics Financial Statements
Bicara Therapeutics investors use historical fundamental indicators, such as Bicara Therapeutics' Net Debt, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Bicara Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Debt | -440.1 M | -418.1 M | |
| Net Debt To EBITDA | 5.35 | 3.15 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Bicara Stock Analysis
When running Bicara Therapeutics' price analysis, check to measure Bicara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicara Therapeutics is operating at the current time. Most of Bicara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicara Therapeutics' price. Additionally, you may evaluate how the addition of Bicara Therapeutics to your portfolios can decrease your overall portfolio volatility.